{"DataElement":{"publicId":"6704128","version":"1","preferredName":"Mycosis Fungoides and Sezary Syndrome AJCC Edition 8 Lymph Node N Category","preferredDefinition":"Extent of the lymph node involvement for mycosis fungoides and sezary syndrome using AJCC Ed. 8 criteria.","longName":"MFSS_AJC8_N_CAT","context":"NCI Standards","contextVersion":"1","DataElementConcept":{"publicId":"6702717","version":"1","preferredName":"Mycosis Fungoides and Sezary Syndrome N Category","preferredDefinition":"Mature T and NK neoplasms predominantly affecting the skin and the peripheral blood.  Peripheral blood involvement by abnormal T-cells (cerebriform cells) is a late manifestation of mycosis fungoides, whereas it is the presenting finding in Sezary syndrome. --2003_One criteria of the TNM staging system. N refers to the extent of lymph node involvement.","longName":"6702710v1.0:2678076v1.0","context":"NCI Standards","contextVersion":"1","ObjectClass":{"publicId":"6702710","version":"1","preferredName":"Mycosis Fungoides and Sezary Syndrome","preferredDefinition":"Mature T and NK neoplasms predominantly affecting the skin and the peripheral blood.  Peripheral blood involvement by abnormal T-cells (cerebriform cells) is a late manifestation of mycosis fungoides, whereas it is the presenting finding in Sezary syndrome. --2003","longName":"C9265","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mycosis Fungoides and Sezary Syndrome","conceptCode":"C9265","definition":"Mature T and NK neoplasms predominantly affecting the skin and the peripheral blood.  Peripheral blood involvement by abnormal T-cells (cerebriform cells) is a late manifestation of mycosis fungoides, whereas it is the presenting finding in Sezary syndrome.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"86CE9C6C-F805-26F5-E053-F662850A0B07","latestVersionIndicator":"Yes","beginDate":"2019-04-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-04-18","modifiedBy":"ONEDATA","dateModified":"2019-04-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2678076","version":"1","preferredName":"N Stage","preferredDefinition":"One criteria of the TNM staging system.  N refers to the extent of lymph node involvement.","longName":"C25580","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"N Category","conceptCode":"C25580","definition":"One criteria of the TNM staging system. N refers to the extent of lymph node involvement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3978B81B-DCB6-3E3D-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-06","endDate":null,"createdBy":"UMLLOADER_COCANUT","dateCreated":"2007-09-06","modifiedBy":"ONEDATA","dateModified":"2007-09-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"86D272B0-D4BB-5B18-E053-F662850ABD9C","latestVersionIndicator":"Yes","beginDate":"2019-04-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-04-18","modifiedBy":"COOPERM","dateModified":"2019-04-25","changeDescription":"4-18-19 created for standardization; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6703454","version":"1","preferredName":"Mycosis Fungoides and Sezary Syndrome American Joint Committee on Cancer Edition 8 N Category","preferredDefinition":"A finding about one or more characteristics of mycosis fungoides and Sezary syndrome, following the rules of the TNM AJCC v8 classification system as they pertain to staging of peripheral lymph nodes._A group formed for the purpose of developing a system of clinical staging for cancer that is acceptable to the American medical profession and is compatible with other accepted classifications._One criteria of the TNM staging system. N refers to the extent of lymph node involvement._A grouping of items based on some commonality or by user defined characteristics.","longName":"6703454v1.0","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"2","maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"N3","valueDescription":"Mycosis Fungoides and Sezary Syndrome N3 TNM Finding v8","ValueMeaning":{"publicId":"6704071","version":"1","preferredName":"Mycosis Fungoides and Sezary Syndrome N3 TNM Finding v8","longName":"6704071","preferredDefinition":"Clinically abnormal peripheral lymph nodes; histopathology Dutch grades 3-4 or NCI LN4; clone positive or negative. Note: EORTC N3 classification includes: Dutch grade 3: partial effacement of lymph node architecture; many atypical cerebriform mononuclear cells. Dutch grade 4: complete effacement of lymph node. NCI LN4: partial/complete effacement of nodal architecture by atypical lymphocytes or frankly neoplastic cells. (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mycosis Fungoides and Sezary Syndrome N3 TNM Finding v8","conceptCode":"C141320","definition":"Clinically abnormal peripheral lymph nodes; histopathology Dutch grades 3-4 or NCI LN4; clone positive or negative. Note: EORTC N3 classification includes: Dutch grade 3: partial effacement of lymph node architecture; many atypical cerebriform mononuclear cells. Dutch grade 4: complete effacement of lymph node. NCI LN4: partial/complete effacement of nodal architecture by atypical lymphocytes or frankly neoplastic cells. (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"86E1FCEA-32D6-5D5C-E053-F662850AB71C","latestVersionIndicator":"Yes","beginDate":"2019-04-19","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-04-19","modifiedBy":"COOPERM","dateModified":"2019-04-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"86E1FCEA-32EF-5D5C-E053-F662850AB71C","beginDate":"2019-04-19","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-04-19","modifiedBy":"ONEDATA","dateModified":"2019-04-19","deletedIndicator":"No"},{"value":"N2b","valueDescription":"Mycosis Fungoides and Sezary Syndrome N2b TNM Finding v8","ValueMeaning":{"publicId":"6704073","version":"1","preferredName":"Mycosis Fungoides and Sezary Syndrome N2b TNM Finding v8","longName":"6704073","preferredDefinition":"Clone positive. Note: A T-cell clone is defined by polymerase chain reaction (PCR) or Southern blot analysis of the TCR gene. (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mycosis Fungoides and Sezary Syndrome N2b TNM Finding v8","conceptCode":"C141319","definition":"Clone positive. Note: A T-cell clone is defined by polymerase chain reaction (PCR) or Southern blot analysis of the TCR gene. (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"86E1FCEA-32FC-5D5C-E053-F662850AB71C","latestVersionIndicator":"Yes","beginDate":"2019-04-19","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-04-19","modifiedBy":"ONEDATA","dateModified":"2019-04-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"86E1FCEA-3315-5D5C-E053-F662850AB71C","beginDate":"2019-04-19","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-04-19","modifiedBy":"ONEDATA","dateModified":"2019-04-19","deletedIndicator":"No"},{"value":"N2a","valueDescription":"Mycosis Fungoides and Sezary Syndrome N2a TNM Finding v8","ValueMeaning":{"publicId":"6704075","version":"1","preferredName":"Mycosis Fungoides and Sezary Syndrome N2a TNM Finding v8","longName":"6704075","preferredDefinition":"Clone negative. Note: A T-cell clone is defined by polymerase chain reaction (PCR) or Southern blot analysis of the TCR gene.  (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mycosis Fungoides and Sezary Syndrome N2a TNM Finding v8","conceptCode":"C141318","definition":"Clone negative. Note: A T-cell clone is defined by polymerase chain reaction (PCR) or Southern blot analysis of the TCR gene.  (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"86E1FCEA-3322-5D5C-E053-F662850AB71C","latestVersionIndicator":"Yes","beginDate":"2019-04-19","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-04-19","modifiedBy":"ONEDATA","dateModified":"2019-04-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"86E1FCEA-333B-5D5C-E053-F662850AB71C","beginDate":"2019-04-19","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-04-19","modifiedBy":"ONEDATA","dateModified":"2019-04-19","deletedIndicator":"No"},{"value":"N2","valueDescription":"Mycosis Fungoides and Sezary Syndrome N2 TNM Finding v8","ValueMeaning":{"publicId":"6704077","version":"1","preferredName":"Mycosis Fungoides and Sezary Syndrome N2 TNM Finding v8","longName":"6704077","preferredDefinition":"Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 2 or NCI LN3. Note: EORTC N2 classification includes Dutch grade 2: dermatopathic lymphadenopathy; early involvement by mycosis fungoides (presence of cerebriform nuclei less than 7.5 micrometers). NCI LN3: aggregates of atypical lymphocytes; nodal architecture preserved. (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mycosis Fungoides and Sezary Syndrome N2 TNM Finding v8","conceptCode":"C141316","definition":"Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 2 or NCI LN3. Note: EORTC N2 classification includes Dutch grade 2: dermatopathic lymphadenopathy; early involvement by mycosis fungoides (presence of cerebriform nuclei less than 7.5 micrometers). NCI LN3: aggregates of atypical lymphocytes; nodal architecture preserved. (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"86E1FCEA-3348-5D5C-E053-F662850AB71C","latestVersionIndicator":"Yes","beginDate":"2019-04-19","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-04-19","modifiedBy":"COOPERM","dateModified":"2019-04-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"86E1FCEA-3361-5D5C-E053-F662850AB71C","beginDate":"2019-04-19","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-04-19","modifiedBy":"ONEDATA","dateModified":"2019-04-19","deletedIndicator":"No"},{"value":"N1b","valueDescription":"Mycosis Fungoides and Sezary Syndrome N1b TNM Finding v8","ValueMeaning":{"publicId":"6704079","version":"1","preferredName":"Mycosis Fungoides and Sezary Syndrome N1b TNM Finding v8","longName":"6704079","preferredDefinition":"Clone positive. Note: A T-cell clone is defined by polymerase chain reaction (PCR) or Southern blot analysis of the TCR gene. (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mycosis Fungoides and Sezary Syndrome N1b TNM Finding v8","conceptCode":"C141315","definition":"Clone positive. Note: A T-cell clone is defined by polymerase chain reaction (PCR) or Southern blot analysis of the TCR gene. (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"86E1FCEA-336E-5D5C-E053-F662850AB71C","latestVersionIndicator":"Yes","beginDate":"2019-04-19","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-04-19","modifiedBy":"ONEDATA","dateModified":"2019-04-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"86E1FCEA-3387-5D5C-E053-F662850AB71C","beginDate":"2019-04-19","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-04-19","modifiedBy":"ONEDATA","dateModified":"2019-04-19","deletedIndicator":"No"},{"value":"N1a","valueDescription":"Mycosis Fungoides and Sezary Syndrome N1a TNM Finding v8","ValueMeaning":{"publicId":"6704081","version":"1","preferredName":"Mycosis Fungoides and Sezary Syndrome N1a TNM Finding v8","longName":"6704081","preferredDefinition":"Clone negative. Note: A T-cell clone is defined by polymerase chain reaction (PCR) or Southern blot analysis of the TCR gene. (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mycosis Fungoides and Sezary Syndrome N1a TNM Finding v8","conceptCode":"C141314","definition":"Clone negative. Note: A T-cell clone is defined by polymerase chain reaction (PCR) or Southern blot analysis of the TCR gene. (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"86E1FCEA-3394-5D5C-E053-F662850AB71C","latestVersionIndicator":"Yes","beginDate":"2019-04-19","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-04-19","modifiedBy":"ONEDATA","dateModified":"2019-04-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"86E1FCEA-33AD-5D5C-E053-F662850AB71C","beginDate":"2019-04-19","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-04-19","modifiedBy":"ONEDATA","dateModified":"2019-04-19","deletedIndicator":"No"},{"value":"N1","valueDescription":"Mycosis Fungoides and Sezary Syndrome N1 TNM Finding v8","ValueMeaning":{"publicId":"6704083","version":"1","preferredName":"Mycosis Fungoides and Sezary Syndrome N1 TNM Finding v8","longName":"6704083","preferredDefinition":"Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 1 or National Cancer Institute (NCI) LN0-2. Note: EORTC N1 classification includes: Dutch grade 1: dermatopathic lymphadenopathy. NCI LN0: no atypical lymphocytes. NCI LN1: occasional and isolated atypical lymphocytes (not arranged in clusters). NCI LN2: many atypical lymphocytes or lymphocytes in 3-6 cell clusters. (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mycosis Fungoides and Sezary Syndrome N1 TNM Finding v8","conceptCode":"C141312","definition":"Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 1 or National Cancer Institute (NCI) LN0-2. Note: EORTC N1 classification includes: Dutch grade 1: dermatopathic lymphadenopathy. NCI LN0: no atypical lymphocytes. NCI LN1: occasional and isolated atypical lymphocytes (not arranged in clusters). NCI LN2: many atypical lymphocytes or lymphocytes in 3-6 cell clusters. (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"86E1FCEA-33BA-5D5C-E053-F662850AB71C","latestVersionIndicator":"Yes","beginDate":"2019-04-19","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-04-19","modifiedBy":"COOPERM","dateModified":"2019-04-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"86E1FCEA-33D3-5D5C-E053-F662850AB71C","beginDate":"2019-04-19","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-04-19","modifiedBy":"ONEDATA","dateModified":"2019-04-19","deletedIndicator":"No"},{"value":"N0","valueDescription":"Mycosis Fungoides and Sezary Syndrome N0 TNM Finding v8","ValueMeaning":{"publicId":"6704085","version":"1","preferredName":"Mycosis Fungoides and Sezary Syndrome N0 TNM Finding v8","longName":"6704085","preferredDefinition":"No clinically abnormal peripheral lymph nodes; biopsy not required. Note: for node, abnormal peripheral lymph node(s) indicates any palpable peripheral node that on physical examination is firm, irregular, clustered, fixed or 1.5 cm or larger in diameter. Node groups examined on physical examination include cervical, supraclavicular, epitrochlear, axillary, and inguinal. Central nodes, which generally are not amenable to pathological assessment, currently are not considered in the nodal classification unless used to establish N3 histopathologically. (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mycosis Fungoides and Sezary Syndrome N0 TNM Finding v8","conceptCode":"C141311","definition":"No clinically abnormal peripheral lymph nodes; biopsy not required. Note: for node, abnormal peripheral lymph node(s) indicates any palpable peripheral node that on physical examination is firm, irregular, clustered, fixed or 1.5 cm or larger in diameter. Node groups examined on physical examination include cervical, supraclavicular, epitrochlear, axillary, and inguinal. Central nodes, which generally are not amenable to pathological assessment, currently are not considered in the nodal classification unless used to establish N3 histopathologically. (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"86E1FCEA-33E0-5D5C-E053-F662850AB71C","latestVersionIndicator":"Yes","beginDate":"2019-04-19","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-04-19","modifiedBy":"COOPERM","dateModified":"2019-04-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"86E1FCEA-33F9-5D5C-E053-F662850AB71C","beginDate":"2019-04-19","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-04-19","modifiedBy":"ONEDATA","dateModified":"2019-04-19","deletedIndicator":"No"},{"value":"NX","valueDescription":"Mycosis Fungoides and Sezary Syndrome NX TNM Finding v8","ValueMeaning":{"publicId":"6703464","version":"1","preferredName":"Mycosis Fungoides and Sezary Syndrome NX TNM Finding v8","longName":"6703464","preferredDefinition":"Clinically abnormal peripheral lymph nodes; no histologic confirmation. (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mycosis Fungoides and Sezary Syndrome NX TNM Finding v8","conceptCode":"C141310","definition":"Clinically abnormal peripheral lymph nodes; no histologic confirmation. (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"86D49923-2898-089E-E053-F662850AD879","latestVersionIndicator":"Yes","beginDate":"2019-04-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-04-18","modifiedBy":"COOPERM","dateModified":"2019-04-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"86D49923-28B1-089E-E053-F662850AD879","beginDate":"2019-04-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-04-18","modifiedBy":"ONEDATA","dateModified":"2019-04-18","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"6703453","version":"1","preferredName":"Mycosis Fungoides and Sezary Syndrome Lymph Nodes TNM Finding v8 American Joint Committee on Cancer N Category Category","preferredDefinition":"A finding about one or more characteristics of mycosis fungoides and Sezary syndrome, following the rules of the TNM AJCC v8 classification system as they pertain to staging of peripheral lymph nodes.:A group formed for the purpose of developing a system of clinical staging for cancer that is acceptable to the American medical profession and is compatible with other accepted classifications.:One criteria of the TNM staging system. N refers to the extent of lymph node involvement.:A grouping of items based on some commonality or by user defined characteristics.","longName":"C141309:C39315:C25580:C25372","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mycosis Fungoides and Sezary Syndrome Lymph Nodes TNM Finding v8","conceptCode":"C141309","definition":"A finding about one or more characteristics of mycosis fungoides and Sezary syndrome, following the rules of the TNM AJCC v8 classification system as they pertain to staging of peripheral lymph nodes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"American Joint Committee on Cancer","conceptCode":"C39315","definition":"A group formed for the purpose of developing a system of clinical staging for cancer that is acceptable to the American medical profession and is compatible with other accepted classifications.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"N Category","conceptCode":"C25580","definition":"One criteria of the TNM staging system. N refers to the extent of lymph node involvement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Category","conceptCode":"C25372","definition":"A grouping of items based on some commonality or by user defined characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"86D52631-863C-62CC-E053-F662850A8422","latestVersionIndicator":"Yes","beginDate":"2019-04-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-04-18","modifiedBy":"ONEDATA","dateModified":"2019-04-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"86D52631-864D-62CC-E053-F662850A8422","latestVersionIndicator":"Yes","beginDate":"2019-04-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-04-18","modifiedBy":"COOPERM","dateModified":"2019-04-25","changeDescription":"4-18-19 created for standardization; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811685","version":"1","longName":"CCR","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]},{"publicId":"5574838","version":"1","longName":"Staging/Extent of Disease","context":"NCI Standards","ClassificationSchemeItems":[{"publicId":"6005920","version":"1","longName":"AJCC Edition 8","context":"NCI Standards"},{"publicId":"6702791","version":"1","longName":"Mycosis Fungoides and Sezary Syndrome","context":"NCI Standards"}]}],"AlternateNames":[{"name":"CCR","type":"USED_BY","context":"CCR"}],"ReferenceDocuments":[{"name":"N category","type":"Preferred Question Text","description":"N category","url":null,"context":"NCI Standards"},{"name":"C3D Question Text","type":"Alternate Question Text","description":"Node","url":null,"context":"CCR"}],"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"86E2CF55-A97C-66D0-E053-F662850AEEFF","latestVersionIndicator":"Yes","beginDate":"2019-04-19","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-04-19","modifiedBy":"COOPERM","dateModified":"2019-04-25","changeDescription":"4-19-19 created for standardization; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}